In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics & Biosimilars

Biosimilars are changing the US market, after a slower entry than in Europe. Leaders from Sandoz and Viatris share exclusive insights on strategies for 2022. Also see who is leading the pack in the latest Generics Bulletin top 50 rankings.

View Rankings




Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

US Biosimilars Enjoy A Year Of Firsts In 2021

While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.

Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review

Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.

Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars

As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Chapter sponsored by:

Fueling The Growth Of Generics Post-COVID

Generics companies have played a pivotal role during the global pandemic, ensuring essential medicines are accessible for patients as the health care industry faces ongoing challenges.

Download Now

About West Pharmaceutical Services

West is a leading global manufacturer in the design and production of technologically advanced, high quality, integrated containment and delivery systems for injectable medicines.

Learn More »

Outlook 2022 e-Book

Outlook 2022 cover

Download a PDF copy of the Outlook 2022 collection, including Scrip 100 league tables.

ACCESS NOW




UsernamePublicRestriction

Register